Press "Enter" to skip to content

Amgen’s AMG420 shows responses in myeloma trial, gets FDA fast track

Amgen also said that AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.

Original source: https://health.economictimes.indiatimes.com/news/pharma/amgens-amg420-shows-responses-in-myeloma-trial-gets-fda-fast-track/66932666?utm_source=RSS&utm_medium=ETRSS

Also Read:   Hope of Covid-19 vaccine deployment in UK by New Year: Report